Recently, the results of a study on the role of drug O in gastric cancer immunity** have attracted widespread attention. The study was the first to report the four-year overall survival rate of patients with gastric cancer, and the results showed that drug O has a significant advantage in prolonging patient survival.
The drug, nivolumab, is an immuno** drug that targets PD-1. By activating the patient's own immune system, O can recognize and attack cancer cells, thereby controlling tumor growth and prolonging survival. In the field of gastric cancer**, the research of O drugs has been attracting much attention.
In this latest study, the researchers conducted long-term follow-up of gastric cancer patients who received drug O**. The results showed that patients who received drug O** performed well in the four-year survival rate. Compared with traditional chemotherapy, drug O significantly improved the survival of patients, and the quality of life of patients in the process of ** was also significantly improved.
Specifically, looking at the OS data of the Chinese subgroup, up to 1 in 4 (25%) of patients with PD-L1 CPS 5 who received drug O in combination with chemotherapy achieved 4-year long-term survival, which was twice as much as that of the chemotherapy alone group (11%)[1]! Of course, the advantage is not limited to this population, for all patients (including patients with PD-L1 CPS 5), the combination of drug O and chemotherapy is also advantageous, and the 4-year survival rate is also more than twice that of chemotherapy (21% vs.). 9%）。
It can be seen that in the survival chart, regardless of the expression of PD-L1, the distance between the blue line (O drug combined with chemotherapy group) and the gray line (chemotherapy alone group) is always wide, and the advantage of survival benefit is very clearThis is enough to give us great confidence, and the "long" of long-term survival is by no means just talk.
It is worth mentioning that O drug** is not suitable for all patients with gastric cancer. At present, drug O is mainly used for patients with gastric cancer who have progressed after chemotherapy. For patients with early-stage gastric cancer, surgery and chemotherapy remain the preferred methods, the researchers said. For patients with advanced gastric cancer, drug O provides a new way.
Despite the encouraging results of the drug in the field of stomach cancer, the researchers caution patients and doctors to remain rational
In conclusion, the results of the four-year overall survival rate of drug O in gastric cancer immunity** bring new hope to patients. With the in-depth research and the accumulation of clinical experience, it is believed that O drug will play a greater role in the field of gastric cancer** and bring a better survival experience to more patients.